Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Scienture Holdings, Inc. reported the quarter ended March 31, 2023 results: revenue $2.2 million, net income ($0.7) million, EPS ($0.07) per basic and diluted share.
- Period
- the quarter ended March 31, 2023
- Revenue
- $2.2 million
- Net income
- ($0.7) million
- EPS
- ($0.07) per basic and diluted share
- Result
- reported results
Exact text from the filing
First Quarter 2023 Financial Summary Consolidated revenues for the first quarter of 2023 compared to the first quarter of 2022 decreased 31% to $2.2 million, compared to $3.2 million, respectively. The decrease in consolidated revenue was driven by decreased revenue attributed to our Trxade Prime subsidiary. The revenues generated by the TRxADE Platform in the first quarter of 2023 compared to 2022 increased 4% and Trxade Prime year over year revenue declined 70% in 2023 compared to 2022. The subsidiary company Community Specialty Pharmacy experienced a 16% increase in revenue for the first quarter 2023 compared to 2022. Gross profit analysis of comparable fiscal periods of 2023 and 2022 reflect an increase in gross profits of $221,000 for the first quarter of 2023 compared to 2022. As a percent of revenue, consolidated gross profit increased to 69% for the comparable quarter periods of 2023 and 2022. Operating expenses for the first quarter of 2023 were $1.9 million, compared to $2.3
View on SEC.gov